Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease.
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PACS11UNIRAD; UNIRAD
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 1931.
- 02 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2021.